Systematic review of immune checkpoint inhibitors in cancer efficacy and safety
Immune Checkpoint Inhibitors Show Promise For Cancer Patients With High Tumor Burden
This systematic review synthesizes evidence from 15 randomized trials and cohort studies on immune checkpoint inhibitors in cancer. It finds…
A review of trials suggests immune checkpoint inhibitors work well for some cancer patients but carry risks like skin rashes and organ infla…
Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
New analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth
This meta-analysis evaluates dual immune checkpoint inhibitor therapy versus control treatments in patients with advanced or metastatic non-…
A large review of 6,369 patients found that using two immune checkpoint drugs together improved survival time compared to standard treatment…
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Systematic review examines immune checkpoint inhibitors, innate immunity, and immune-related adverse events in cancer patients
A review suggests innate immunity plays a key role in cancer drug side effects
This systematic review evaluated immune checkpoint inhibitors (ICIs) in patients with cancer, focusing on immune-related adverse events (irA…
Cancer drugs that help fight tumors can also cause serious inflammation, and new research shows the body's first line of defense plays a key…
Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients
Why Liver Cancer Stops Responding to Immunotherapy — and What Could Change That
This systematic review evaluated drug resistance mechanisms and strategies to overcome resistance in patients with hepatocellular carcinoma …
Understanding why liver cancer learns to dodge the immune system's attack is the first step toward treatments that can keep working long-ter…